KNE Archives - Page 2 of 2

Feature

Kane Biotech completes 12-month transformation; ready for robust growth

Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...

December 10, 2019

Developments

Kane Biotech selected to receive conditional award of up to $3.4 million for DispersinB development

Kane Biotech (TSX-V:KNE) was selected to receive an award of up to about $3.4-million from an unnamed government agency for the continuing clinical development of DispersinB to treat biofilm mediated antimicrobial...

December 3, 2019

Developments

Kane Biotech retains GR Consulting to seek partnerships for DispersinB wound care hydrogel

Kane Biotech (TSXV:KNE) retained GR Consulting to develop and implement an out-licensing strategy for its DispersinB wound care hydrogel for both the U.S. and European markets. “Gary and Edwin have years of experience...

October 31, 2019

Developments

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...

October 16, 2019

Executive Moves

Kane Biotech strengthens animal health and quality assurance team

Kane Biotech (TSXV:KNE) added to its management team, hiring Lori Christofalos as the director of quality and compliance; Shabnam Bashiri as manager of quality control; and Michel Stebenne as VP of animal health. Ms...

August 12, 2019

Developments

Kane Biotech gets $3.8-million Canadian government funding

Kane Biotech (TSXV:KNE) received $3.8-million in funding from Western Economic Diversification Canada to assist the company in expanding from the animal health sector into the human health sector with DispersinB, a...

August 6, 2019

Developments

Kane Biotech in sales representation pact with SLA Brands

Kane Biotech (TSXV:KNE) entered a strategic partnership with Schiaffino, Lasky, & Associates (SLA Brands) to exclusively represent Kane’s bluestem line of products to distributors and retailers in the U.S. market...

April 24, 2019

Tag - KNE

Kane Biotech completes 12-month transformation; ready for robust growth

Kane Biotech selected to receive conditional award of up to $3.4 million for DispersinB development

Kane Biotech retains GR Consulting to seek partnerships for DispersinB wound care hydrogel

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Kane Biotech strengthens animal health and quality assurance team

Kane Biotech gets $3.8-million Canadian government funding

Kane Biotech in sales representation pact with SLA Brands

General

More